[PSYCHOPHARMACOLOGY OF ANTIPARKINSONIAN DRUGS]
Abstract:
Parkinson's disease as an extrapyramidal pathology is accompanied by some non-motor symptoms (depression, cognitive disorders, and sleep disturbance), which are based on disturbances of nigrostriatal dopaminergic neurotransmission supplemented by disorganization of other neuromediator systems. Traditional antiparkinsonian drugs with different cellular mechanism of action are capable of restricting these symptoms in patients and on animal models, while exhibiting their own psychotropic activity. This circumstance should be taken into account in assessing the pharmacological activity profiles of drugs.
Related Concept Videos
Pharmacokinetics: Drug–Drug Interactions
Bioequivalence of Drugs: Drugs with Multiple Indications
FDA Approved Drugs: Changes to Approved Drugs
Factors Influencing Drug Absorption: Drug Dissolution
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions


